Last year, in May, the foreign parent of Fresenius Kabi, an Indian oncology drugs company, announced its intention to sell up to 15% promoter stake and reduce its shareholding to 75% via one or more OFS.
first published: Jun 22, 2013 02:50 pm
A collection of the most-viewed Moneycontrol videos.
PM Modi Condemns Attacks on Qatar, Reaffirms Peace and Stability
“Too Late” for Talks: Trump Says Iran Military, Leadership Gone
Live: Sensex, Nifty drop over 1% amid Iran-US tensions; India VIX soars | Closing Bell
‘Pharma Has A Great Future in India Given Our Quality Of Talent & Our Low Manufacturing Cost’: Ajay Piramal
